loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
Open ICICI 3-in-1 Account

Aarti Industries Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Aarti Industries Ltd. 04 May 2026 18:43 PM
Result PDF

Q4FY26 & FY26 Result Announced for Aarti Industries Ltd.

Specialty Chemicals company Aarti Industries announced Q4FY26 & FY26 results

Standalone Financial Highlights:

  • Total Income: For Q4FY26, the company reported a total income of Rs 2,439 crore, representing a YoY increase of 22.26% from Rs 1,995 crore in Q4FY25 and a QoQ growth of 7.02% from Rs 2,279 crore in Q3FY26. On an annual basis, total income for FY26 stood at Rs 8,430 crore, up 15.09% from Rs 7,325 crore in FY25.
  • Net Revenue from Operations: Net revenue for Q4FY26 was Rs 2,439 crore, showing a YoY growth of 22.44% compared to Rs 1,992 crore in Q4FY25 and a QoQ growth of 7.16% compared to Rs 2,276 crore in Q3FY26. Annual net revenue for FY26 reached Rs 8,422 crore, an increase of 15.34% over Rs 7,302 crore in FY25.
  • Net Profit: The company earned a net profit of Rs 147 crore in Q4FY26, a YoY increase of 48.48% from Rs 99 crore in Q4FY25 and a QoQ increase of 12.21% from Rs 131 crore in Q3FY26. Annual net profit for FY26 was Rs 422 crore, growing by 24.12% compared to Rs 340 crore in FY25.
  • Earnings Per Share (EPS): Basic EPS for Q4FY26 stood at Rs 4.05, while the annual basic EPS for FY26 was Rs 11.65, compared to Rs 9.37 in FY25.
  • Profit Before Tax (PBT): PBT for Q4FY26 was Rs 119 crore, a YoY growth of 29.35% from Rs 92 crore and a QoQ growth of 2.59% from Rs 116 crore. For FY26, standalone PBT stood at Rs 365 crore.

Consolidated Financial Highlights:

  • Total Income: Consolidated total income for Q4FY26 was Rs 2,205 crore, a YoY growth of 12.96% from Rs 1,952 crore in Q4FY25, but a QoQ decline of 5.00% from Rs 2,321 crore in Q3FY26. Annual consolidated total income for FY26 reached Rs 8,291 crore, up 13.78% from Rs 7,287 crore in FY25.
  • Net Revenue from Operations: For Q4FY26, consolidated net revenue stood at Rs 2,206 crore, up 13.19% YoY from Rs 1,949 crore and down 4.87% QoQ from Rs 2,319 crore. Annual consolidated net revenue for FY26 was Rs 8,286 crore, a growth of 13.99% compared to Rs 7,269 crore in FY25.
  • Net Profit: Consolidated net profit for Q4FY26 was Rs 137 crore, representing a YoY increase of 42.71% from Rs 96 crore and a QoQ growth of 3.01% from Rs 133 crore. Annual consolidated net profit for FY26 reached Rs 419 crore, reflecting a 26.59% increase over Rs 331 crore in FY25.
  • Earnings Per Share (EPS): Consolidated annual basic EPS for FY26 was Rs 11.56, compared to Rs 9.13 in FY25.
  • Profit Before Tax (PBT): Consolidated PBT for Q4FY26 reached Rs 111 crore, showing a YoY growth of 26.14% from Rs 88 crore and a QoQ decline of 5.93% from Rs 118 crore.

Business Highlights

  • Segment Performance: The company reported that it operates in only one reportable segment, which is 'Specialty Chemicals'.
  • Dividend Recommendation: The Board of Directors has recommended a dividend of Re 1/- per equity share (20%) of face value of Rs 5/- each for FY26, subject to shareholder approval.
  • Commercial Paper: The company repaid all commercial papers on their respective due dates during the period. As of March 31, 2026, listed commercial papers worth Rs 300 crore were outstanding.
  • Equity Share Allotment: During Q4FY26, 500 equity shares were issued and allotted under the 'Aarti Industries Limited Performance Stock Option Plan 2022', bringing the total paid-up share capital to Rs 1,81,29,71,845/-.
  • Subsidiary Network: As of March 31, 2026, the company has seven direct subsidiaries, two indirect subsidiaries, and two joint ventures.

Result PDF

Result PDF

Specialty Chemicals company Aarti Industries announced Q3FY26 results

  • Revenue stood at Rs 2,492 crore, an increase of 11% QoQ driven by volume growth across various value chains.
  • EBITDA surged to Rs 323 crore, marking a 11% QoQ increase.
  • Profit After Tax for the quarter, driven by higher operational performances, surged to Rs 133 crore, an increase of 25% QoQ.

Suyog Kotecha, Executive Director & Chief Executive Officer, said: “The global operating environment continues to remain volatile, shaped by geopolitical uncertainties and ongoing trade realignments. Despite these challenges, Aarti Industries has delivered resilient performance, supported by proactive market diversification and a calibrated approach to the U.S. Our ability to sustain volumes and maintain customer engagement reflects the strength of our integrated portfolio and execution discipline.

Our strategic focus is shifting from bulk, product-led growth to a more streamlined, knowledge-driven and quality-focused portfolio. We are actively managing volatility through downstream integration, portfolio diversification and a sharper focus on highervalue chemistries, while deepening customer engagements through chemistry-led, R&D-oriented solutions. With Jhagadia, Zone IV emerging as a transformational growth platform, strong demand visibility for new products and disciplined capital allocation, we remain confident in our long-term growth trajectory. Recent Policy developments in China and ongoing progress on trade agreements such as the EU FTA are expected to support margin recovery and long term growth opportunities”

Result PDF

Specialty Chemicals company Aarti Industries announced Q2FY26 results

  • Revenue: Rs 2,250 crore, up 21% QoQ, led by improved volumes across key product categories.
  • EBITDA: Rs 292 crore, up 36% QoQ, reflecting higher capacity utilisation and cost optimisation.
  • PAT: Rs 105 crore, up 150 % QoQ, driven by better operating leverage and after considering exceptional items (as detailed in the financials declared earlier).
  • CAPEX: Rs 267 crore for the quarter; FY26 outlay expected below Rs 1,000 crore, reflecting continued capital discipline.

Suyog Kotecha, Executive Director & Chief Executive Officer, said: “This quarter reflected the inherent resilience and agility of our diversified portfolio. Despite US tariff headwinds, our strong customer engagement and proactive regional rebalancing helped us maintain the momentum. We are expanding our footprint in Europe, the Middle East, and Africa while optimising our US strategy to ensure long-term competitiveness. With key capacity additions nearing completion, Aarti Industries is well-positioned to capitalise on the next phase of global recovery. Our focus remains clear: to de-risk operations, accelerate innovation in high-growth chemistries, and maintain strong financial discipline. As trade flows stabilise and demand revives, we anticipate steady margin expansion across our portfolio."

Result PDF

Specialty Chemicals company Aarti Industries announced Q1FY26 results

  • Revenue: Rs 1,867 crore, reflecting near-term impact of raw-material corrections and deferred export flows.
  • EBITDA: Rs 215 crore, with margins affected by input price volatility and temporary operational disruptions.
  • PAT: Rs 43 crore, in line with operational trends and higher interest and depreciation.

Suyog Kotecha, CEO and Executive Director, said: “This was a uniquely challenging quarter shaped by global and regional volatility. Yet, what remained consistent was our commitment to long-term value creation. Our volumes stayed resilient, key capacity expansions are ramping up, and our green and circular initiatives continue progressing as planned. We are already seeing signs of normalisation in customer activity, raw material costs, and logistics, which reinforces our confidence in a stronger performance ahead. With the recent development on the US tariff front, we are closely monitoring the situation to ascertain the impact and plan appropriate actions.”

Result PDF

Specialty Chemicals company Aarti Industries announced Q4FY25 results

Q4FY25 Financial Highlights:

  • Revenue: Rs 2214 crore, marking 9% QoQ and 13% YoY growth.
  • EBITDA: Rs 266 crore, up 13% QoQ, reflecting operating leverage and improved cost controls.
  • PAT: Rs 96 crore, rising 109% sequentially on the back of better volumes and efficiency gains.

Suyog Kotecha, CEO & Executive Director, said: “We are encouraged by the positive momentum across our businesses, particularly the recovery in core product volumes and the continued execution of our expansion and sustainability agenda. FY26 begins amid a volatile macroeconomic environment, US trade barriers, and geopolitical tensions. With a strong pipeline, we are focused on delivering consistent, value-led growth while strengthening our position as a global partner of choice.”

Result PDF

Specialty Chemicals company Aarti Industries announced Q3FY25 results

  • Quarterly revenues at Rs 2,035 crore, marking a 14% increase QoQ.
  • EBITDA grew by 17% QoQ to Rs 236 crore, driven by Volume growth, Operating leverage and Product mix improvements.
  • PAT at Rs 46 crore, a 12% QoQ decrease (impacted by mark to market loss on Longterm ECB Loan of Rs 23 crore arising due to Rupee depreciation).
  • Exports saw sequential growth, while domestic volumes remained stable across most end-use applications.

Suyog Kotecha, CEO and Executive Director of Aarti Industries, said: “In a dynamic global environment, AIL delivered a resilient performance despite market challenges in Q3FY25 with EBITDA growing sequentially on the back of strong volume growth. While pricing pressures weighed on margins, we remain focused on risk mitigation through cost efficiencies, product diversification and geographic expansion into the US, Europe, and Japan markets. With a robust innovation pipeline and sustainability at our core, we are well-positioned to capitalize on future opportunities in high-growth applications.”

Result PDF

Specialty Chemicals company Aarti Industries announced Q4FY23 & FY23 results:

  • Q4FY23:
    • Revenues of Rs 1,826 crore; an increase of 11.2% over Q4FY22
    • EBITDA of Rs 252 crore; a decrease of 3.8% over Q4FY22
    • PAT of Rs 149 crore; an increase of 2.1% over Q4FY22
  • FY23:
    • Revenues of Rs 7,283 crore; an increase of 25.1% over FY22
    • EBITDA of Rs 1,089 crore; a increase of 18.5% over FY22
    • PAT of Rs 545 crore in FY23

Commenting on the performance for Q4FY23, Rajendra Gogri – Chairman & MD at Aarti Industries said: “Financial Year 2023 was a challenging period for the industry guided by unfolding of several material events including Russia-Ukraine conflict, the inflationary surge in input prices & energy costs and slowing demand in few developed markets. Given this backdrop, we reported resilient performance and are glad to have concluded the year on a high with EBITDA of close to Rs 1,100 crore, as guided previously. Despite the challenges due to the pandemic, external market-linked disruptions, supply chain issues, inflationary costs, etc faced in the last five years, our chemical EBIDTA grew from Rs 534 crore in FY18 to Rs 1,089 crore in FY23. This more than 2x growth in EBIDTA is a testament to our robust and resilient business model and our ability to steer onto the growth journey in the most challenging periods.

Our aspiration of driving growth in a sustained and responsible manner, while being future-ready to capitalise on upcoming market opportunities forms the bedrock of success. All our expansion initiatives remain intact. We have operationalized the two speciality chemical process blocks in Q4 FY23. Our other key projects will be commissioned in a phased manner over the next two years as guided earlier. Our focus is to create new chemical value chains and introduce high-potential products to elevate our leadership position within the chosen chemistries. This will result in significant volume growth from the current year FY24 and meaningful accretion to both revenues and earnings, as guided earlier.

We firmly believe that this is a ‘Golden Decade’ for the Indian Chemical industry and our teams are working relentlessly on building scale for select high-potential opportunities backed by our inherent strengths and expertise. Over several years, AIL had been pioneering in introducing various products and chemistries in India and also put India into the Global Market. Our future plans for Chloro-toluene and downstream is one more addition to AIL introducing a newer range of products and complex chemistry for the first time in India and will benefit from the opportunities for import substitution and export opportunities for global markets. Our ability to adapt to the changing market conditions and commitment to delivering quality products and services to our customers has been the cornerstone of our success. As we look ahead, we remain optimistic and are confident of demonstrating sustained earnings growth thereby augmenting value for all our stakeholders.”

 

 

Result PDF

Specialty chemical firm Aarti Industries announced Q3FY23 results:

  • Q3FY23:
    • Revenues of Rs 1,854 crore; an increase of 12% over the previous year.
    • EBITDA of Rs 289 crore; an increase of 26% over the previous year.
    • PAT of Rs 137 crore.
      • Revenue grew on a YoY basis on account of inflated RM prices, utility costs, freight costs, etc. On QoQ, despite some corrections in prices, revenues were maintained on account of a higher mix of value-added products.
      • Performance was also steered by higher contributions from the legacy products targeting essential end-user segments due to continued better operating environment; incremental revenues from newly added capacities further aided the performance momentum.
      • Product offtake linked to the Textiles industry like Dyes and Pigments remains subdued, as directed in the previous quarter. The same is expected to start recovering over the next two to three quarters.
    • Witnessed QoQ decline in some input costs and logistics, while few still remained elevated during the quarter. The company has robust pricing mechanisms in place to mitigate the impact of these inflationary cost pressures, and the same is being passed on to the customers thereby protecting absolute profitability.
    • EBITDA improvement was significant, which came on the back of our dynamic product mix and our efforts to mitigate the global challenges to push for a few high-value products while the demand for a few of the products remains subdued.
    • Depreciation as guided earlier is in line with the new capacities commissioned. While Finance costs had an impact of M2M loss of about Rs 11 crore in respect of the unhedged ECBs.
    • Various growth initiatives like NCB capacity expansion and specialty chemicals plants are ongoing. These are expected to come on stream over the next two quarters and will start revenues in a phased manner from H1FY24.

Commenting on the performance for Q3 FY23, Rajendra Gogri, Chairman & MD at Aarti Industries Limited, said: “We have demonstrated sustained performance build-up during the period under review, with strong gains in both topline and profitability metrices despite softness in demand across few end-user categories. I am glad how our teams have swiftly reacted to this changing operating scenario and channelized their vast industry experience to deliver a resilient performance. New capacity lines added in the past few quarters have started contributing to the overall performance and this will ramp up in the ensuing period. We witnessed a moderation in some input cost line items, while inflation in other costs persisted. We expect this to stabilize soon, the impact of which will be evident in the ensuing period.

Our historic partnership on Nitric Acid off-take will significantly benefit us in the long run and ensure that we remain adequately fueled to achieve our ambitious growth projections. On a separate note, I am pleased to share that we have commercialized the facility linked to the 3rd Long-Term Contract at Jhagadia, a positive contribution of which will start unfolding from the next financial year.

Our growth aspirations are huge, and we are making all the right investments to ensure that we further cement our leadership position in the chosen chemistries, while leveraging our expertise in some of the high-potential newer chemical value chains where the addressable opportunity is humongous. The coming two years will see maximum gains arising from various CAPEX projects announced in the past. Overall, we remain confident of delivering what is expected out of us through a combination of our expertise in manufacturing and process enhancements, blended with strength in R&D and innovation. Our objective is to increase shareholder value by capitalizing on the positive sector tailwinds.”

Result PDF

Specialty chemical firm Aarti Industries announced Q2FY23 results:

  • Q2FY23:
    • Revenues of Rs 1,847 crore; an increase of 29% over the previous year
    • EBITDA of Rs 267 crore; an increase of 5% over the previous year
    • PAT of Rs 124 crore

Rajendra Gogri, Chairman & MD at Aarti Industries Ltd, said: “Q2 of the current fiscal year has been an eventful period for us. Not only have we delivered a stable financial performance, but also received NCLT approval to demerge our Pharma business into a separate entity – Aarti Pharmalabs Limited, thereby significantly enhancing value for our stakeholders while also achieving operational efficiencies. This will help the companies take appropriate strategic decisions in view of the growth opportunities available under the respective businesses.

The external environment continues to be challenging aggravated by high costs both on raw materials and utilities side, moderate slowdown in some end-user industries related to textiles combined with severe forex fluctuations and other global uncertainties. Against this backdrop, our performance has been resilient. Stability in performance over the years is an outcome of robust proficiency achieved in handling multiple chemistries with manufacturing excellence. Our execution capabilities and delivery commitments are best-in-class, and our customers trust us for that. We remain the go-to players for them when it comes to chemistries linked to Benzene and Toluene product chains among others. Our capex initiatives are well on track, and this will steer the performance momentum in the forthcoming period. Work is underway to create newer chemical value chains and also introduce high-potential products to expand the addressable market opportunity while catering to increased demand from key customers. We expect full benefit of our expansion program to unfold in FY24 and FY25 as we anticipate demand recovery from Q4 of the current fiscal year. Further, with the volume ramp-up for the new capacities coming in significantly in FY24 and FY25, while fixed costs will generally not increase significantly, the gross profit to EBITDA conversion will improve in FY24 and beyond

We will continue to remain agile, while capitalising on opportunities created through swift movement in the Indian chemical industry landscape. Our R&Dp-led product profile combined with incremental gains from existing value-chains will set the tone and improve our value proposition going ahead.”

 

Result PDF

Specialty Chemicals firm Aarti Industries announced Q1FY23 Result :

  • Significant increase in revenues was on account of pass-on for the elevated Inputs prices, Utility costs and Logistics costs.
  • Commenced commercial production at the new block of the USFDA approved API facility at Tarapur in early Q2; this will further strengthen Company’s niche offerings in Pharma
  • The project related to 1st and 2nd long term contract has started seeing volume ramp up; utilisation levels expected to increase to ~70% by the end of FY24
  • Revenues of Rs. 2,173 crore; increase of 45% over previous year
  • EBITDA of Rs. 369 crore; growth of 18% over previous year
  • PAT of Rs. 189 crore; up by 15% over previous year

Commenting on the performance for Q1 FY23, Mr. Rajendra Gogri – Chairman & MD at Aarti Industries Limited said: “I am pleased to share that we started the new financial year on an encouraging note with healthy topline growth of 45% YoY and EBITDA improvement of 18% YoY in Q1 of FY23. This strong performance has come on the back of challenging operating environment premised on continued inflationary pressure in key raw materials and other utilities combined with logistical disruptions and global uncertainties. The global inflationary trend and recession fears have resulted in modest slowdown in demand from some end user segments. Given this backdrop, our performance has been resilient, and I would like to congratulate our workforce for demonstrating agility and traversing through these pressures to deliver stellar performance in a tough environment. We remain committed to drive over businesses through challenging situations and deliver robust performances.

Based on strong business visibility, we had charted our growth plans and CAPEX deployment is underway to accomplish our longterm goals. We will see new capacities being commissioned in a phase-wise manner from this financial year that will elevate our performance trajectory. In addition, we are also expanding our product portfolio, introducing new high-potential and complex chemical value-chains, and strengthening our R&D capabilities to cement our leadership position in the chosen chemistries. Our planned investments close to ~Rs. 3,000 crore in the over two years are on track, that will define our growth strategy.

Overall, we are well placed to capture incremental market share based on our superior execution capabilities combined with planned scale-up for key products and addition of niche chemical value-chains. We strongly believe in the growth potential of the Indian Chemical & Pharma industry and will endeavor to make significant inroads to deliver sustained profitability.”

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app